-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Kidney Transplant in Kidney Transplant Rejection
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Kidney Transplant in Kidney Transplant Rejection report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Kidney Transplant in Kidney Transplant Rejection Drug Details: The therapeutic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TD-5202 in Crohn’s Disease (Regional Enteritis)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TD-5202 in Crohn's Disease (Regional Enteritis) Drug Details: TD-5202 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TD-5202 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TD-5202 in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TD-5202 in Ulcerative Colitis Drug Details:TD-5202 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FX-5A in Atherosclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FX-5A in Atherosclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.FX-5A in AtherosclerosisDrug Details:FX-5A is under development for the treatment of atherosclerosis and heart...
-
Company Profile
Theravance Biopharma Inc – Company Profile
Theravance Biopharma Inc (Theravance Biopharma) is a biopharmaceutical company that discovers, develops, and markets organ-selective medicines for the treatment of inflammation and immune system disorders and specializes in developing respiratory medicines. The company is investigating its pipeline candidates for the treatment of asthma, neurogenic orthostatic hypotension (nOH), gastrointestinal motility disorders, ulcerative colitis, heart failure, chronic kidney disease (CKD), Crohn’s disease and gastroparesis and concurrent bacteremia. Theravance Biopharma has agreements with other pharmaceutical companies and holds economic interests in potential future...
Add to Basket -
Product Insights
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. The Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline drugs market research report provides comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or...
-
Product Insights
Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. The Hypertension pipeline market research report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TD-5202
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry TD-5202 Drug Details TD-5202 is under development for the treatment of celiac disease, ulcerative...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ampreloxetine hydrochloride
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ampreloxetine hydrochloride Drug Details Ampreloxetine HCL (TD-9855) was under development for the treatment of...
-
Product Insights
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The risk factors of Methicillin-Resistant Staphylococcus Aureus (MRSA) are hemodialysis, weakened immune system, admission to hospitals, and wounds. Symptoms include skin rashes, fatigue, chest pain, fever, and swelling. MRSA can be managed using antibiotics and by maintaining hygienic conditions The Methicillin-Resistant Staphylococcus Aureus pipeline market research report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus Aureus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The...